Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be pricing in less than the company's fundamentals could justify.
-
Viatris is up 76.1% over the last 12 months, which puts more focus on whether the recent share price better reflects the company's long term earnings power.
-
Recent product news, including the FDA approval of the Gwyn Lo contraceptive patch and the agreement to transfer rights to TYRVAYA nasal spray, can support expectations for future cash flows, while execution risk around new launches and portfolio reshaping may limit how much investors are willing to pay today.
-
On Simply Wall St's valuation checks, Viatris screens as undervalued in 5 of 6 areas , so the broader set of metrics leans toward the stock still looking cheap relative to its fundamentals.
The issue now is whether Viatris' current share price already reflects these positives or if the valuation still leaves a margin of safety.
Does Viatris Look Undervalued on Sales?
The P/S ratio can be a helpful way to think about Viatris because it links what you pay for the stock to the revenue the company already generates.
Viatris trades on a P/S of about 1.3x, which sits well below the Pharmaceuticals industry average of 5.0x and also under the peer group average of 4.7x. On Simply Wall St's preferred benchmark, the fair P/S ratio for Viatris is estimated at 3.5x, which is materially higher than where the stock is currently priced.
Even with recent product news such as the FDA approval of the Gwyn Lo contraceptive patch helping sentiment, the market is still valuing each dollar of Viatris revenue at a sizable discount to what peers command and to the model's fair ratio. The gap suggests investors are pricing in meaningful execution and portfolio reshaping risk, while the broader valuation checks point to a company that may be stronger than the multiple implies.
On the P/S multiple, Viatris stock appears undervalued compared with both its industry and the tailored fair ratio benchmark.
See what the numbers say about this price — find out in our valuation breakdown.
The Viatris Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Viatris valuation puzzle leaves off by spelling out what would need to happen to Viatris' growth, margins and earnings for the stock to be worth materially more or less than today's price. Rather than relying on a single multiple or model output, each Narrative lays out the key assumptions behind its view of fair value so you can compare those expectations with actual results over time.
Community views on Viatris sit far apart, with some investors focused on cash generation and others worried about pressure on the generics business.
Bull case: 58% undervalued
"Viatris continued to generate massive cash flows and used them to reduce debt, stabilize margins, and invest selectively in new areas such as biosimilars and cardiovascular treatments..."
Read the full Bull Case to see why Viatris could be undervalued
Bear case: 37% overvalued
"Sustained pricing and regulatory pressures are likely to compress margins and increase operating costs across Viatris' core generics business..."
Read the full Bear Case to see why Viatris could be overvalued
Do you think there's more to the story for Viatris? Head over to our Community to see what others are saying!
The Bottom Line
For Viatris, the valuation work so far points to a stock that still screens as undervalued on market multiples, even after the recent strength. The key question is whether the discount reflects temporary caution or a lasting concern about execution and portfolio reshaping. If Viatris can turn its product pipeline and reshaped portfolio into steadier cash flows without major setbacks, the current gap to peers may eventually narrow. If those efforts fall short, the present discount could reflect the market correctly pricing the risk rather than an obvious opportunity.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VTRS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
